Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap

Levosimendan is a distinctive inodilator combing calcium sensitization, phosphodiesterase inhibition and vasodilating properties through the opening of adenosine triphosphate-dependent potassium channels. It was first approved in Sweden in 2000 for the short-term treatment of acutely decompensated s...

Descripción completa

Detalles Bibliográficos
Autores principales: Conti, Nicolina, Gatti, Milo, Raschi, Emanuel, Diemberger, Igor, Potena, Luciano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350150/
https://www.ncbi.nlm.nih.gov/pubmed/34376973
http://dx.doi.org/10.2147/DDDT.S295214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350150/
https://www.ncbi.nlm.nih.gov/pubmed/34376973
http://dx.doi.org/10.2147/DDDT.S295214

Ejemplares similares